{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:47:36Z","timestamp":1787064456407,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pelvic exenteration (PE) offers a potential cure for selected patients with Locally Advanced Rectal Cancer (LARC) or Locally Recurrent Rectal Cancer (LRRC) invading adjacent pelvic organs. Despite advances in surgical technique and perioperative care, PE remains associated with significant morbidity. This study evaluates long-term oncologic outcomes of PE over 20 years at a high-volume tertiary cancer center in India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed 97 patients who underwent PE between January 2000 and December 2020. Patients included those with LARC or LRRC, where R0 resection was deemed feasible. Surgical procedures were classified as total pelvic exenteration (TPE) or modified pelvic exenteration (MPE). Data on demographics, operative parameters, pathological features, recurrence pattern and survival were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 97 patients (median age 59; 80.4% male), 67% had LARC and 33% LRRC. R0 resection was achieved in 71.1%. TPE was more common in LRRC, while MPE predominated in LARC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014). Common complications included pelvic collection (25.8%) and wound infection (15.5%). The 5-year OS was higher in R0 resection patients (51.9% vs. 12.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013) and those with LARC vs. LRRC (57.0% vs. 10.6%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032). LRRC had higher recurrences post R0 resection. In the multivariate analysis, the only independent predictors of OS were the initial presentation of the disease and R0 resection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PE remains a curative strategy for LARC and LRRC following an R0 resection. LRRC is associated with higher recurrence and poorer survival. Optimal outcomes require multidisciplinary evaluation, margin-negative resection, and tailored surgical approaches. This study provides data from a low- and middle-income country setting, where such literature remains limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-025-04053-0","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T08:26:00Z","timestamp":1764318360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes and survival trends following pelvic exenteration for locally advanced and recurrent rectal cancer: a 20-Year analysis from a tertiary cancer center in India"],"prefix":"10.1186","volume":"24","author":[{"given":"M.D","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"3","key":"4053_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4053_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.6061\/clinics\/2017(05)01","volume":"72","author":"CSR Nahas","year":"2017","unstructured":"Nahas CSR, Nahas SC, Ribeiro-Junior U, et al. Prognostic factors affecting outcomes in multivisceral en bloc resection for colorectal cancer. Clinics. 2017;72(5):258\u201364. https:\/\/doi.org\/10.6061\/clinics\/2017(05)01.","journal-title":"Clinics"},{"issue":"8","key":"4053_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ejso.2012.05.001","volume":"38","author":"M Cukier","year":"2012","unstructured":"Cukier M, Smith AJ, Milot L, et al. Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience. Eur J Surg Oncol. 2012;38(8):677\u201382. https:\/\/doi.org\/10.1016\/j.ejso.2012.05.001.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"4053_CR4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ejso.2016.02.016","volume":"42","author":"AJ Quyn","year":"2016","unstructured":"Quyn AJ, Austin KK, Young JM, et al. Outcomes of pelvic exenteration for locally advanced primary rectal cancer: overall survival and quality of life. Eur J Surg Oncol. 2016;42(6):823\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2016.02.016.","journal-title":"Eur J Surg Oncol"},{"key":"4053_CR5","doi-asserted-by":"publisher","unstructured":"Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948;1(2):177\u201383. https:\/\/doi.org\/10.1002\/1097-0142(194807)1:2%3C;177::aid-cncr2820010203%3E;3.0.co;2-a.","DOI":"10.1002\/1097-0142(194807)1:2%3C;177::aid-cncr2820010203%3E;3.0.co;2-a"},{"issue":"6","key":"4053_CR6","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.21037\/jgo.2019.01.21","volume":"10","author":"YC Lau","year":"2019","unstructured":"Lau YC, Brown KGM, Lee P. Pelvic exenteration for locally advanced and recurrent rectal cancer-how much more? J Gastrointest Oncol. 2019;10(6):1207\u201314. https:\/\/doi.org\/10.21037\/jgo.2019.01.21.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"4053_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/s1072-7515(99)00229-x","volume":"190","author":"WL Law","year":"2000","unstructured":"Law WL, Chu KW, Choi HK. Total pelvic exenteration for locally advanced rectal cancer. J Am Coll Surg. 2000;190(1):78\u201383. https:\/\/doi.org\/10.1016\/s1072-7515(99)00229-x.","journal-title":"J Am Coll Surg"},{"issue":"17","key":"4053_CR8","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731\u201340. https:\/\/doi.org\/10.1056\/NEJMoa040694.","journal-title":"N Engl J Med"},{"key":"4053_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104196","volume":"192","author":"L Boublikova","year":"2023","unstructured":"Boublikova L, Novakova A, Simsa J, Lohynska R. Total neoadjuvant therapy in rectal cancer: the evidence and expectations. Crit Rev Oncol Hematol. 2023;192:104196. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104196.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"23","key":"4053_CR10","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO.22.00506","volume":"40","author":"A Aref","year":"2022","unstructured":"Aref A, Abdalla A. Total neoadjuvant therapy for locally advanced rectal cancer: induction or consolidation chemotherapy? J Clin Oncol. 2022;40(23):2515\u20139. https:\/\/doi.org\/10.1200\/JCO.22.00506.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4053_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/DCR.0000000000000839","volume":"60","author":"KGM Brown","year":"2017","unstructured":"Brown KGM, Solomon MJ, Koh CE. Pelvic exenteration surgery: the evolution of radical surgical techniques for advanced and recurrent pelvic malignancy. Dis Colon Rectum. 2017;60(7):745\u201354. https:\/\/doi.org\/10.1097\/DCR.0000000000000839.","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"4053_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1503\/cjs.014010","volume":"54","author":"TS Domes","year":"2011","unstructured":"Domes TS, Colquhoun PH, Taylor B, et al. Total pelvic exenteration for rectal cancer: outcomes and prognostic factors. Can J Surg. 2011;54(6):387\u201393. https:\/\/doi.org\/10.1503\/cjs.014010.","journal-title":"Can J Surg"},{"issue":"5","key":"4053_CR13","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1245\/s10434-018-07090-0","volume":"26","author":"Y Kulu","year":"2019","unstructured":"Kulu Y, Mehrabi A, Khajeh E, et al. Promising long-term outcomes after pelvic exenteration. Ann Surg Oncol. 2019;26(5):1340\u20139. https:\/\/doi.org\/10.1245\/s10434-018-07090-0.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"4053_CR14","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1007\/s00268-009-0066-7","volume":"33","author":"FT Ferenschild","year":"2009","unstructured":"Ferenschild FT, Vermaas M, Verhoef C, et al. Total pelvic exenteration for primary and recurrent malignancies. World J Surg. 2009;33(7):1502\u20138. https:\/\/doi.org\/10.1007\/s00268-009-0066-7.","journal-title":"World J Surg"},{"issue":"2","key":"4053_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/SLA.0000000000002528","volume":"269","author":"PelvEx Collaborative","year":"2019","unstructured":"PelvEx Collaborative. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration. Ann Surg. 2019;269(2):315\u201321. https:\/\/doi.org\/10.1097\/SLA.0000000000002528.","journal-title":"Ann Surg"},{"issue":"6","key":"4053_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/bjs.10734","volume":"105","author":"PelvEx Collaborative","year":"2018","unstructured":"PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg. 2018;105(6):650\u20137. https:\/\/doi.org\/10.1002\/bjs.10734.","journal-title":"Br J Surg"},{"issue":"10","key":"4053_CR17","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/bjs.9841","volume":"102","author":"RW Radwan","year":"2015","unstructured":"Radwan RW, Jones HG, Rawat N, et al. Determinants of survival following pelvic exenteration for primary rectal cancer. Br J Surg. 2015;102(10):1278\u201384. https:\/\/doi.org\/10.1002\/bjs.9841.","journal-title":"Br J Surg"},{"issue":"12","key":"4053_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/j.ejso.2019.07.015","volume":"45","author":"PS Waters","year":"2019","unstructured":"Waters PS, Peacock O, Warrier SK, et al. Evolution of pelvic exenteration surgery- resectional trends and survival outcomes over three decades. Eur J Surg Oncol. 2019;45(12):2325\u201333. https:\/\/doi.org\/10.1016\/j.ejso.2019.07.015.","journal-title":"Eur J Surg Oncol"},{"issue":"23","key":"4053_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233906","volume":"16","author":"C Coco","year":"2024","unstructured":"Coco C, Rizzo G, Amodio LE, Pafundi DP, Marzi F, Tondolo V. Current management of locally recurrent rectal cancer. Cancers (Basel). 2024;16(23):3906. https:\/\/doi.org\/10.3390\/cancers16233906.","journal-title":"Cancers (Basel)"},{"key":"4053_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1556386","volume":"16","author":"T Wang","year":"2025","unstructured":"Wang T, Chen Z, Wang W, Wang H, Li S. Single-cell and spatial transcriptomic analysis reveals tumor cell heterogeneity and underlying molecular program in colorectal cancer. Front Immunol. 2025;16:1556386. https:\/\/doi.org\/10.3389\/fimmu.2025.1556386.","journal-title":"Front Immunol"},{"issue":"3","key":"4053_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s13193-022-01529-3","volume":"13","author":"G Das","year":"2022","unstructured":"Das G, Sahewalla A, Purkayastha J, et al. Pelvic exenteration for locally advanced rectal cancer: an initial experience from North-east India. Indian J Surg Oncol. 2022;13(3):559\u201363. https:\/\/doi.org\/10.1007\/s13193-022-01529-3.","journal-title":"Indian J Surg Oncol"},{"issue":"34","key":"4053_CR22","doi-asserted-by":"publisher","first-page":"8688","DOI":"10.1200\/JCO.2005.02.1329","volume":"23","author":"C R\u00f6del","year":"2005","unstructured":"R\u00f6del C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688\u201396. https:\/\/doi.org\/10.1200\/JCO.2005.02.1329.","journal-title":"J Clin Oncol"},{"key":"4053_CR23","doi-asserted-by":"publisher","unstructured":"Tie J, Cohen JD, Wang Y et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer published correction appears in JAMA Oncol. 2019;5(12):1811. doi: 10.1001\/jamaoncol.2019.5667.. JAMA Oncol. 2019;5(12):1710\u20131717. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3616.","DOI":"10.1001\/jamaoncol.2019.3616"},{"issue":"5","key":"4053_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/bjs5.75","volume":"2","author":"D Steffens","year":"2018","unstructured":"Steffens D, Solomon MJ, Young JM, et al. Cohort study of long-term survival and quality of life following pelvic exenteration. BJS Open. 2018;2(5):328\u201335. https:\/\/doi.org\/10.1002\/bjs5.75.","journal-title":"BJS Open"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04053-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04053-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04053-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T19:02:30Z","timestamp":1767466950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04053-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4053"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04053-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a retrospective observational analysis of previously recorded clinical data, and no direct patient contact or intervention was involved. As per institutional policy and national guidelines, IEC clearance is not mandatory for retrospective studies using anonymized data. However, all data handling was performed in compliance with ethical standards ensuring patient confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}